MaxCyte Latest News

This strategic acquisition strengthens MaxCyte’s ability to serve ex vivo and in vivo cell and gene therapy (CGT) developers with an innovative suite of tools and services spanning early R&D through clinical development and commercialization. By integrating SeQure Dx into MaxCyte, Maxcyte will expand its service offerings and leverage its commercial and field application scientist teams to work with developers earlier in their research processes. SeQure Dx is revenue generating and expected to be accretive to MaxCyte’s revenue growth.

In the last three months, new collaboration between the University of California San Diego Sanford Stem Cell Institute (SSCI) and MaxCyte, Webinar on Next-Generation genetic discovery systems in human immune cells, Scientific poster on High efficiency complex gene editing of hard-to-transfect primary cells using MaxCyte electroporation in combination with Synthego sgRNAs.

Jeremy Kolenbrander is Senior VP of Product Development and Engineering at MaxCyte, he was drawn to cell and gene therapy as it has the ability to make a huge difference in the lives of patients and their caregivers. He joined MaxCyte in early in 2024.

MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.

New collaboration aims to improve patient outcomes and boost biopharma workforce development.

Cynthia Collins joins the board with extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years.

Ali Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the company’s market impact in cell and gene therapy.

In the last three months, Kamau Therapeutics became a strategic platform licensee partner, Porton Advance adopted the ExPERT GTx Flow Electroporation as part of their offerings, and ScaleReady and MaxCyte have collaborated on the G-Rex Grant Program to support cell and gene therapy advancements.

Marina Prasek is a project and portfolio management leader with demonstrated success in new product development and commercialization that joined MaxCyte in January of 2024.

MaxCyte and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, announce they are entering into a strategic platform license (SPL) agreement.